Wachovia Ups Biogen Idec to 'Outperform'

Analyst Martin Auster says the company will be one of the few large-cap biotechs with accelerating EPS trends over the next few years

Wachovia upgraded Biogen Idec (BIIB ) to outperform from market perform. Yesterday the company and Elan (ELN ) said they expect to submit an application to FDA for approval of Antegren by mid-2004.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.